Trofinetide
Brand names: Daybue, Daybue Stix · Active ingredient: Trofinetide
In short: DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
What is Trofinetide used for?
DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
Trofinetide dosage
The recommended dosage of DAYBUE or DAYBUE STIX is based on patient weight as shown in Table 1. Administer DAYBUE or DAYBUE STIX orally or via gastrostomy (G) tube twice daily, in the morning and evening, with or without food. Doses administered via gastrojejunal (GJ) tubes must be administered through the G-port.
Patient Weight | Recommended Dosage
9 kg to less than 12 kg | 5,000 mg twice daily
12 kg to less than 20 kg | 6,000 mg twice daily
20 kg to less than 35 kg | 8,000 mg twice daily
35 kg to less than 50 kg | 10,000 mg twice daily
50 kg or more | 12,000 mg twice daily
Table 2 includes the volume of DAYBUE oral solution to administer for the corresponding recommended dosage . A calibrated measuring device, such as an oral syringe or oral dosing cup, should be obtained from the pharmacy to measure and deliver the prescribed dose accurately. A household measuring cup, teaspoon, or tablespoon is not an adequate measuring device.
Dosage | DAYBUE Oral Solution Volume
2,500 mg twice dailyDosage for patients with moderate renal impairment | 12.5 mL twice daily
3,000 mg twice daily | 15 mL twice daily
4,000 mg twice daily | 20 mL twice daily
5,000 mg twice daily | 25 mL twice daily
6,000 mg twice daily | 30 mL twice daily
8,000 mg twice daily | 40 mL twice daily
10,000 mg twice daily | 50 mL twice daily
12,000 mg twice daily | 60 mL twice daily
Discard any unused DAYBUE oral solution after 14 days of first opening the bottle .
Prior to administration, DAYBUE STIX for oral solution powder must be dissolved in a cold to room temperature water or water-based beverage (juice, tea, lemonade, limeade, or liquid hydration).
Preparation of DAYBUE STIX
Determine the correct dosage as shown in Table 1 or Table 4 (for patients with moderate renal impairment).
Select the appropriate packet strength and number of packets required for each dose, as shown in Table 3.
Determine the appropriate volume of liquid within the recommended volume range as shown in Table 3, based on individual patient factors (e.g., age, palatability).
Measure the volume of liquid determined in Step 3 by using a calibrated measuring device obtained from the pharmacy.
Empty the entire contents of the DAYBUE STIX packet(s) into the measured liquid. Do not attempt to use partial packets to prepare a dose.
Stir until the powder is completely dissolved.
Administer the prepared oral solution immediately; do not store for future use.
Discard any prepared oral solution that is not immediately administered.
Dose | DAYBUE STIX Packet(s) Needed to Prepare Each Dose | Volume of Liquid Required to Dissolve Entire Dose
Liquid types include water or water-based beverage.
,
Volume should be selected within the recommended range based on individual patient factors. …
How to take Trofinetide — instructions & advice from the label
Advise the caregiver or patient to read the FDA-approved patient labeling (Patient Information).
Preparation and Administration
Advise the caregiver or patient that DAYBUE or DAYBUE STIX may be given orally or via gastrostomy (G) tube; doses administered via gastrojejunal (GJ) tubes must be administered through the G-port. DAYBUE or DAYBUE STIX may be taken with or without food .
Instruct the caregiver or patient to obtain a calibrated measuring device, such as an oral syringe or oral dosing cup, from the pharmacy. A household measuring cup, teaspoon, or tablespoon is not an adequate measuring device .
DAYBUE Oral Solution
Instruct the caregiver or patient to discard any unused DAYBUE oral solution after 14 days from first opening the bottle.
DAYBUE STIX for Oral Solution
Advise the caregiver or patient that DAYBUE STIX for oral solution powder must be dissolved in a cold to room temperature water or water-based beverage (juice, tea, lemonade, limeade, or liquid hydration) prior to administration . Instruct the caregiver or patient on how much water or water-based beverage is needed to dissolve the contents of DAYBUE STIX packet(s). …
Warnings & precautions
Do not take this medicine if: None.
In Study 1 and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was of mild or moderate severity in 96% of cases. In Study 1, antidiarrheal medication was used in 51% of patients treated with DAYBUE.
Advise patients to stop laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if severe diarrhea occurs or if dehydration is suspected .
In Study 1, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss.
Monitor weight and interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if significant weight loss occurs .
In Study 1, vomiting occurred in 29% of patients treated with DAYBUE and in 12% of patients who received placebo .
Patients with Rett syndrome are at risk for aspiration and aspiration pneumonia. Aspiration and aspiration pneumonia have been reported following vomiting in patients being treated with DAYBUE. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if vomiting is severe or occurs despite medical management .
Trofinetide side effects
The following clinically significant adverse reactions are described elsewhere in labeling:
Diarrhea
Weight Loss
Vomiting
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In controlled and uncontrolled trials in patients with Rett syndrome, 260 patients ages 2 to 40 years were treated with DAYBUE, including 112 patients treated for more than 6 months, 92 patients treated for more than 1 year, and 44 patients treated for more than 2 years.
The safety of DAYBUE STIX has been established from an adequate, well-controlled study, and open-label studies of DAYBUE . Below is a display of the adverse reactions of DAYBUE in these studies.
Adult and Pediatric Patients with Rett Syndrome 5 Years of Age and Older
The safety of DAYBUE was evaluated in a randomized, double-blind, placebo-controlled, 12-week study of patients with Rett syndrome (Study 1) . In Study 1, 93 patients received DAYBUE and 94 patients received placebo. All patients were female, 92% were White, and the mean age was 11 years (range 5 to 20 years).
Adverse Reactions Leading to Discontinuation of Treatment
Eighteen patients (19%) receiving DAYBUE had adverse reactions that led to withdrawal from the study. …
Drug interactions
CYP3A and/or P-gp Substrates
Closely monitor patients when DAYBUE or DAYBUE STIX is administered concomitantly with sensitive CYP3A and/or P-gp substrates where minimal increases in the plasma concentration of these substrates may lead to serious adverse reactions. Trofinetide, a weak inhibitor of CYP3A and an inhibitor of P-gp, increased the plasma concentrations of CYP3A and/or P-gp substrates , which may increase the risk of adverse reactions associated with these substrates.
About this medicine
DAYBUE oral solution and DAYBUE STIX for oral solution contain the active moiety trofinetide. The chemical name of trofinetide is (2S)-2-{[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino}pentanedioic acid (IUPAC). The molecular formula of trofinetide is C13H21N3O6 and its molecular weight is 315.33 g/mol. The chemical structure is shown below.
Trofinetide is a white to off-white solid and is freely soluble in water.
DAYBUE oral solution is pink to red in color and contains 1 g of trofinetide in each 5 mL of solution (200 mg/mL). The oral solution also contains FD&C Red No. 40, maltitol, methylparaben sodium, propylparaben sodium, purified water, strawberry flavor, and sucralose as inactive ingredients.
DAYBUE STIX for oral solution is a white, off-white to pinkish powder to be dissolved in a cold to room temperature water or water-based beverage before administration and contains 5,000 mg, 6,000 mg, or 8,000 mg of trofinetide in each packet. The for oral solution powder contains natural strawberry flavor and sucralose as inactive ingredients. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 67e6f2d9-21f6-466f-9def-826c6a4b8257. Read the full official label on DailyMed.